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Abstract
Background: People with overweight or obesity are at increased risk for disease later in life which cause important
health costs.
The aim of this study was to estimate the health status and the corresponding costs in a sample of females with
overweight or obesity which were participating in a Randomized Controlled Trial (RCT) exploring the effect of
lifestyle habits changes on ectopic adipose tissue.
Methods: Sixty-two non-diabetic premenopausal females without major comorbidities of overweight and obesity
were recruited among patients visiting endocrinologists at the obesity clinic of the University Hospital of Antwerp
and the University of Antwerp.
A RCT-embedded cost-of-illness approach with societal perspective, based on self-reported questionnaires and cost
diaries (3 months recall) was applied to estimate the prevalence of different comorbidities and the related direct
and indirect costs in this sample of overweight or obese females. The European Quality-of-Life-5D questionnaire
was used to define the health state and the corresponding utility index of the participants.
Results: The average direct health costs and health utilities observed in this sample were comparable with the
general Flemish female population. This may partially be explained by the strict inclusion criteria of the RCT (i.e.
overweight or obesity without diabetes type 2 or cardiovascular diseases). However, 15% of the participants had
five or more comorbidities resulting in higher average costs and lower average health utility as compared to the
general population, only 3 participants were diagnozed with the metabolic syndrome. In this subsample
productivity was low due to high average absenteeism, yielding important total costs for the society.
Conclusion: Secondary prevention to avoid health deterioration in overweight or obese females without major
comorbidies is needed to contain health care costs.
Trial registration: ClinicalTrials.gov: NCT02831621, approval of the ethics committee of the University Hospital of
Antwerp (number: 14/17/205 -ref: 7543075363).
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Background
The increasing prevalence of overweight and obesity
during the last decades has become a serious public
health concern and has placed a financial burden on the
wider economy [1, 2].
The association between overweight or obesity and
health disorders such as the metabolic syndrome has
been well established.
In Flanders, the northern Dutch speaking part of
Belgium, the prevalence of overweight (BMI ≥ 25 kg.m−
2) and obesity (BMI ≥ 30 kg.m− 2) in the female popula-
tion (aged 35 to 44 years) is estimated at 42.5 and 11.4%
respectively [3].
The extent to which overweight and obesity related
metabolic abnormalities are seen defines the patient’s
global cardiometabolic risk profile [4]. In this regard, a
distinction is made between metabolically healthy obes-
ity (MHO) and obese people suffering from the meta-
bolic syndrome [5]. The prevalence of the metabolic
syndrome in a population increases in people with
higher BMI and age and is a marker for high health care
utilization and costs in people with overweight [6, 7].
In general, overweight and obesity are associated with
high direct and indirect costs. Direct costs include the
costs of the diagnosis and treatment of overweight and
obesity and especially their associated diseases and com-
plications, while the indirect costs are those resulting
from productivity loss such as work absenteeism, early
retirement, and the lost value of life due to premature
mortality [8, 9]. In European countries, this cost may
range from 0.7 to 0.8% of the total annual expenses of
the health insurers [10].
Although, overweight resulted in 7.4% of the
Disability-Adjusted Life Year (DALY) in Belgium in 2004,
the cost of overweight or obesity is as yet not well under-
stood [10].
Especially information on the health costs in the over-
weight or obese population without major comorbidities is
still lacking. The economic burden of a disease or condition
can be estimated by cost-of-illness studies [11]. In general
two approaches are used in cost-of-illness studies, namely
the prevalence-based and the incidence-based approach.
Prevalence-based studies estimate the costs associated with
past and current consequences of the disease or condition
in a given time period, typically a year. The incidence-based
approach estimates the costs and consequences associated
with new cases of the disease or condition in the current
and future years [12]. Insights into the economic impact of
overweight and obesity are important to strengthen the
knowledge of the current burden associated with this con-
dition and may inform decision makers to understand the
scale of overweight or obesity related problems. This may
help them to establish evidence-based public health policies
to tackle the overweight and obesity problem.
The aim of this paper was to estimate the health status
(i.e. the comorbidities) and the corresponding costs in a
sample of 62 premenopausal non-diabetic overweight or
obese females in Flanders. This paper was the first step
towards a complete cost-effectiveness and cost-utility
analysis of an intervention (diet and physical activity) to
reduce body weight, abdominal and ectopic adipose tis-
sue in this sample.
Methods
Theoretical framework
Figure 1 depicts the theoretical framework that was
followed in this study. A bottom-up cost-of-illness
approach was applied to estimate the prevalence of
Fig. 1 Components of cost analysis
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different comorbidities and the related direct and indir-
ect costs in this sample of overweight and obese females.
Direct medical costs include expenses for visits to
physicians or medication. Direct non-medical costs in-
clude for example the use of braces if needed in condi-
tions of morbid obesity. Indirect costs encompass
productivity loss (e.g. premature mortality, absenteeism
or presenteeism) or leisure time loss. Intangible costs
refer to costs related to pain or psychological suffering
(e.g. stigmatization), however the latter is difficult to
measure and will not be analysed in this present study.
A prevalence-based approach was used to examine the
costs of overweight and obesity in premenopausal women
in the Flanders region. A prevalence-based study estimates
the economic burden of a disease or condition over a
well-defined time period, in this case three months [13].
Study participants
The study was conducted in the larger Antwerp metro-
politan area in Flanders.
Study participants were recruited among patients visit-
ing endocrinologists at the obesity clinic of the University
Hospital of Antwerp between May 2016 and August 2016.
In addition, poster recruitment was performed in the
University Hospital of Antwerp and the University of
Antwerp. A total of 120 participants responded and
wanted to volunteer in this study.
Table 1 shows the inclusion and exclusion criteria for
the selection of the study participants. All included par-
ticipants were non-diabetic premenopausal overweight
or obese females. Since fitness training was part of the
intervention and an individually but standardized exer-
cise scheme was followed, women were excluded when
suffering from cardiovascular diseases or musculoskel-
etal disorders that made strength or endurance training
impossible. This selection procedure resulted in a sam-
ple size of 62 participants.
All included participants (n = 62) were randomized to a
hypocaloric dietary intervention group or a combination
group of hypocaloric diet and increased physical activity
and they were measured at baseline, in between (3 months)
and at the end of the intervention (6 months). After the
intervention period, participants were followed up during
6 months and measured in between this period (9 months)
and at the end of the study (12 months).
This study was the first step of a trial-embedded
health economic evaluation. Its protocol has been de-
scribed and published elsewhere [14]. The protocol and
consent forms were approved by the ethical committee
of the University Hospital Antwerp (approval number:
14/17/205). All participants gave prior written consent.
Data collection
Data were gathered by means of self-reported question-
naires (cost diary) at baseline, during the intervention
and follow up. In this paper, results from baseline
questionnaires (3) are discussed. Questionnaires were
based on similar questionnaires used in a study from
the University of Ghent in which costs in an obese
population in Flanders were reported [15]. In this
way, our results could be compared with a reference
group of obese people.
One questionnaire with closed questions aimed at
assessing the type of comorbidities over the last three
months. A set of overweight-related (e.g. hypertension,
cardiovascular disorders, gall bladder; cancer; arthritis or
osteoarthritis, depression) and pathologies unrelated to
overweight (e.g. allergy, asthma, chronic obstructive pul-
monary disease (COPD), skin disorders, hypo/hyperthy-
roidism, stomach ulcer, migraine headache) was listed.
Respondents could answer “yes”, “no” or “previously”.
One open question offered the opportunity to add “other
disorders”. A final question asked if the physician gave
advice to start a treatment for overweight or obesity.
Table 1 Inclusion and exclusion criteria of participants
Inclusion Exclusion
women planned pregnancy within one year
BMI > 27 kg/m2 hypothyroidism
age > 18 years diabetes type 2 or prediabetes with medication use
stable body weight, i.e., not varying by > 3% for at least 3 months
prior to the first consultation
changes in medication regimen which can affect study outcomes (e.g. of lipid-
lowering or antihypertensive agents)
premenopausal state defined by hormonal data; FSH > 25 mU/ml
and estradiol < 20 pg/ml
using drugs known to affect body weight and lipid distribution including tricyclic
antidepressant agents
willing to participate in a lifestyle based weight loss intervention
(diet or exercise)
abuses alcohol or has a history of alcohol abuse, i.e., more than 2 alcoholic
consumptions/day or binge drinking
no physical dysfunctions which makes increased physical activity
impossible
exclusion criteria related to MRI and CT
able to read and understand the guidelines given by the dietician
and sign the informed consent
Serious problems or diseases limiting the performance of a standardized training
protocol, for example serious osteoarthritis, heart ischemia, …
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This could be answered by “yes” or “no” while mention-
ing a date.
Another questionnaire focused on the assessment of dir-
ect and indirect costs. Units consumed over the last three
months as well as prices were asked for visits to health
care providers such as physicians, specialists, nurses, dieti-
cians and physiotherapists. Consumption units and prices
of medication were also asked retrospectively over the
same period. Furthermore, consumption and prices of
hospitalization, day hospitalization, surgery and special
diagnostics or medical examinations were assessed over
the same period together with the number of days absent
from work due to any health problems.
The third questionnaire was the European
Quality-of-Life-5D (EQ-5D-5 L). The EQ-5D consists of
five dimensions (mobility, self-care, usual activity, pain/
discomfort, anxiety/depression) on a five level scale (ran-
ging from 1 = no difficulties to 5 = extreme difficulties)
allowing to define a health state and the calculation of a
corresponding utility index (as a proxy of quality of life).
A utility of 1 is equal to perfect health, while 0 stands
for death [16]. Questionnaires were given to the volun-
teers during the first meeting in the laboratory. Partici-
pants were asked to fill out the questionnaires
retrospectively (for the last three months) and to return
the completed questionnaires when visiting the labora-
tory for a second time one week later.
Data analysis
Data management was conducted in three steps. In a
first step one researcher (JB) manually imputed the re-
sults from the questionnaires into a spreadsheet (Micro-
soft Excel 2013). In a second step two researchers (WH,
JT) checked each cell value of the spreadsheet with the
questionnaire and corrected the value if needed. In a
third step, one researcher (JT) conducted a final round
of ad random data checking.
Data from the comorbidity questionnaire were ana-
lysed using a frequency analyses.
Direct medical cost data were presented in 2017 Euros
and all units consumed and unit prices were reported in a
non-aggregated form. If participants did not mention unit
prices of care providers, the fees determined on 01/01/
2017 were searched on the website of the national insti-
tute for health and invalidity assurance (RIZIV) [17–19].
It was assumed that patients consulted accredited phy-
sicians. For assessing the costs of a specialist doctor, the
billing service tariff of the University Hospital of Ant-
werp was applied. According to RIZIV, the federal insti-
tution that organises the mandatory health insurance,
the price for a dietician consultation amounts to 19.66
Euro. In the present study, this is an out-of-pocket ex-
pense for the patient, because such a visit is reimbursed
by Flemish health insurers only in case of diabetes. It
was assumed that the participants visited an accredited
physiotherapist for a 30 min treatment. This price per
visit amounts to 22.26 Euro of which 16.37 Euro is reim-
bursed from the insurer (in case the therapist joined the
RIZIV convention and the patient has right to the
normal reimbursement rate), resulting in a cost for the
patient of 5.89 Euro per visit [20]. Respondents men-
tioned no nursing costs, hence these were not valued.
Medication costs were calculated based on the units
consumed through the Belgian commented online drug
compendium [21]. Costs for hospitalization, surgery,
day-care hospitalization and medical examinations or
diagnostic testing were based on the billing service 2017
tariff of the University Hospital of Antwerp. A mean cost
of one day in a hospital in the Antwerp region was set at
673.00 Euro (medical services not included). No direct
non-medical costs were reported, hence these were not
valued.
Absenteeism was analysed as an indirect cost and
valued as 288.00 Euro per day following the whitepaper
of SECUREX, a company providing social secretary
services in Flanders [22].
The costs were reported over a three months time
span. Costs were analysed from the perspective of the
patient, the health insurer and the society respectively.
Finally, the EQ-5D questionnaire was analysed using
the EQ-5D-5 L crosswalk index value calculator with
social UK tariff [16].
Statistical analysis was performed using SPSS Version
22.0 (IBM SPSS Statistics V22.0). As could be expected,
cost data in this study were not normally distributed.
For pragmatic reasons however, results were presented
as means and the corresponding 95% confidence inter-
vals. To analyse the association between BMI, utility
score, age, number of comorbidities and the cost, Spear-
man rank order correlation coefficients were calculated.
Statistical significance was set at 5%.
Results
A total of 59 out of the 62 females returned the ques-
tionnaires, which were analysed for this study. Their
mean age was 37 years (ranging from 19 to 53 years)
with a mean body mass index of 32.6 kg.m− 2 (measured
values, range from 27 to 44 kg.m− 2). Most of the partici-
pantswere obese (86%) and were residents of the
Antwerp metropolitan region (82%) in Flanders living
outside of the city (62%). About 47% of the participants
hold a higher education (no university) degree while
18% were university degree holders. In the total sample,
four participants (7%) were unemployed at baseline but
two of them found a job during the course of this
intervention study. Also, four students were included in
this study.
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On average, a participant suffered from about three
comorbidities. Only four responders were free of any
comorbidity while six volunteers showed six to eight
comorbidities. Besides diabetes, which was an
exclusion criteria, the following comorbidities of the
questionnaire were not reported: any form of cancer,
COPD, liver cirrhosis, chronic hepatitis, Parkinson
disease and HIV. Since only three subjects had the
metabolic syndrome, the majority of our sample
(95%) were metabolically healthy overweight or obese
women [5]. Table 2 presents the relative prevalence of
the reported comorbidities in this sample. Musculo-
skeletal disorders and allergies seemed to be the most
prominent comorbidities, but also depression, hyper-
tension, skin problems and migraine headache were
highly prevalent. As « other disorders » were men-
tioned: reflux oesophagitis, hypercholesterolemia,
lupus erythematosus, low limb lipoedemia, glaucoma,
eczema (all disorders mentioned once). With the ex-
ception of thyroid disorders, all listed diseases showed
higher prevalence in the sample under investigation
as compared to a reference sample of 1547 represen-
tative for the adult Flemish female population [23]. In
59% of the cases it was the general practitioner who
suggested to start a treatment against the patient’s
overweight or obesity.
On average, respondents consulted a physician once
over the last three months [95%CI: 0.7 to 1.3]. Average
number of visits to a specialist doctor were also reported
to be once in three months [95%CI: 0.4 to 1.6]. In this
three-month period before the start of the intervention,
only three respondents went to a dietician. Of those, two
participants went twice while one person went once. No
visits to a nurse were reported. During this three-month
period the average number of visits to a physiotherapist
was two [95%CI: 0.8 to 3.5].
Medical examination and diagnostic testing over the
last three months was reported by 29% of the respon-
dents. A second examination or test was consumed by
5% of the participants. Hospitalization was needed for
7% of the study participants. For those, length of stay in
the hospital was one (n = 3) to two (n = 1) nights. Two
patients needed surgery, both for shoulder problems.
Three volunteers reported a visit to a day-care hospital
for sleep disorder, liver biopsy and shoulder problems.
About 65% of the participants were on medication
during the past three months. When contraceptives
were not taken into account the prevalence of drug
consumption was reduced to 55%. Two different
drugs were consumed by 42% of the respondents
while 5% of the volunteers consumed seven different
drugs. Table 3 shows the indications and the relative
Table 2 Relative prevalence (%) of reported comorbidities in this sample in reference to the prevalence (%) in the general female
population in Flanders [23]
Comorbidity Study sample Reference of flemish females [23]
Prevalence (%) Prevalence (%)
Hypertension 22.0 18.6
Cardiovascular problems 1.7 1.3
Gall bladder problems 6.8 1.0
Arthritis or osteoarthritis 16.9 10.6
Depression 39.0 7.6
Incontinence 8.5 6.2
Back and neck problems 62.7 25.2
Joint problems 40.7 21.1
Ovarian cysts 6.8 a
Allergy 47.5 16.6
Asthma 3.4 3.1
Skin 28.8 3.3
Thyroid problems 3.4 6.9
Hernia inguinal 10.2 a
Stomach ulcer 13.6 1.4
Kidney stones 5.1 0.5
Migraine 27.1 14.0
Epilepsy 1.7 0.9
aunknown
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prevalence of drug consumption in the sample. Pain
reducing drugs were consumed by 53% of the sample
while medication against depression and hypertension
ranked on the second place (both 17%).
Absenteeism was reported by 13.6% of the partici-
pants. The average number of days absent from work
in this sample over the past three months was 5.5 days
[95% CI: 0.3 to 10.7]. Three participants reported
90 days absenteeism for reasons of depression while
one person remained absent from work during 30 days
because of low back pain.
Table 4 shows the average direct and indirect costs
over the past three months from the perspective of
the patient, the insurers and the society. On average,
a participant of this sample has spent 62.60 Euro for
health care while health insurers paid 280.20 Euro
over the past three months period. If absenteeism is
taken into consideration, the total societal cost for
this sample of premenopausal non-diabetic females
over the last three months was 2239.7 Euro.
The calculated average utility index was 0.83 [95% CI:
0.79 to 0.87]. About 27% of the participants reported to
be in « full health » (i.e. utility index = 1) while 13.5%
had a utility index score lower than 0.70. One person
reported a utility index of 0.34.
Table 5 depicts the Spearman rank order correlation
coefficients matrix between costs, utility index, BMI, age
and number of comorbidities. The results suggested that
societal cost in the sample is negatively but significantly
related to utility scores (i.e. self-reported health status)
while a positive association (albeit not statistically sig-
nificant) between costs for the society and the number
of self reported comorbidities, age and body mass index
were found. Utility was negatively and significantly asso-
ciated with comorbidity, cost of absenteeism as well as
costs from the different perspectives and BMI, a negative
association (p > 0.05) was observed with age. The num-
ber of comorbidities was positively related with cost for
the patient (p < 0.05) and cost for the insurer and society
(p > 0.05) as well as cost from absenteeism (p > 0.05).
The correlation between number of comorbidities and
BMI was positive and statistically significant.
Discussion
Overweight and obesity are important public health issues
and may impose a significant health economic burden to
a society. In this study health status and related costs of
Table 3 Indications and the relative prevalence (%) of drug
consumption in this sample in reference to the general female
prevalence (%)in Flanders [23]
Indication Study sample Population [23]
Prevalence (%) Prevalence (%)
Pain 53.3 3.5
Depression 16.7 3.1
Cardiovascular problems 16.7 11.9
Allergy 13.3 2.4
Stomach problems 11.7 2.7
Infections 6.7 1.6
Endocrine problems 3.3 2.7
Dietary supplements 3.3 a
Birth control 10.0 4.2
Inflammation 13.3 3.6
aunknown
Table 4 Average direct and indirect costs (€) over 3 months from the perspective of the patient, the insurers and the society
measured by recall (3 months) cost diaries
Costs Units consumed Price patient Price insurer Price society
Direct costs
Physician 1.0 4.1 21.4 25.5
Specialist doctor 1.0 11.8 38.9 50.7
Dietician 0.1 2.7 0.0 2.7
Physiotherapist 2.1 12.5 34.7 47.2
Medication a 9.7 14.3 23.9
Hospitalization and surgery 0.1 14.5 52.9 68.4
Day-care hospitalization 0.05 3.0 66.0 69.0
Medical examination 0.3 4.3 52.0 56.3
Subtotal direct costs 62.6 280.2 343.7
Indirect costs
Absenteeism 5.5 0.0 0.0 1552.3
Total direct + Indirect costs 62.6 280.2 2239.7
a unknown, all costs are expressed in Euro (€)
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59 premenopausal non-diabetic overweight or obese
(BMI > 27 kg.m-2) females in Flanders were assessed using
a three months self-reported recall questionnaire. All
results are compared with reference data of the general
female population in Flanders [3, 22, 23] or reference data
from a COI in obese men and women in the larger Ghent
area [15].
Although the majority of the sample (95%) encom-
passes the so-called MHO, the average number of the
self-reported comorbidities was striking. Compared to
the general female population in Flanders, prevalence of
all listed disorders was a factor 0.1 to 10 higher in the
sample under investigation except for thyroid disorders
which was an exclusion criteria. (Table 1) [23]. The most
prevalent complaints were back and neck disorders
(62.7%) and joint problems (40.7%). The findings in this
study corroborate the results of a U.S. study in which
312 obese adults reported to suffer mainly from low
back pain (50%) and joint pain (28%) [24]. The fact that
depressed mood status was about 5 times more preva-
lent (39%) in the sample under investigation than in the
general adult female population (7.6%) [23], supports the
results of a national survey of obese persons in Sweden.
This survey concluded much higher levels of anxiety and
depression in overweight and obese, as well as poorer
perceived health compared with a healthy, non-obese
reference group [25]. Thus, such sample of overweight
and obese females shows higher comorbidity prevalence
compared to the general female population, which may
incur higher health costs [7].
Although diabetes type 2 and cardiovascular diseases
were excluded, the prevalence of other overweight and
obesity related comorbidities in this sample was associ-
ated with increased drug consumption (Table 3). Our
findings suggest an even more important medication use
in people with overweight and obesity than was reported
by Raebel et al. who concluded that on average a person
with obesity compared to a non-obese person consumes
1.81 times more prescription drugs over a one-year time
period [26]. Yearly costs for medication in the sample
was about 96.00 Euro.
The costs from institutionalized care such as
hospitalization and diagnostic examinations totalled on
average 774.80 Euro in this study which are higher than
those in the healthy reference population (571.00 Euro)
[23]. From a societal perspective, the yearly costs for vis-
iting health care professionals in this study was 504.40
Euro. This amount is similar as compared to the same
cost in the general Flemish population (527.00 Euro),
but the contribution of consultations to a specialist
doctor was higher in our sample in comparison with the
general female population in Flanders [23].
The average yearly direct medical costs from the societal
perspective totalled 1374.80 Euro in the present sample of
non-diabetic women with overweight or obesity which is
only about 30% of the total direct costs reported in the
Ghent study [15]. In the latter study, performed in 62
obese diabetic and non-diabetic patients, similar cost diar-
ies were used. In the Ghent study, yearly costs visiting
health care providers (822.00 Euro), yearly medication
costs (300.00 Euro) and yearly costs of institutionalized
care (3200.00 Euro) were much higher than in our study
sample. [15]Main reason for the aberrant differences
between both studies may be the strict inclusion and
exclusion criteria in our study that prevented people with
serious health problems (e.g. ischaemic heart disease and
diabetes) to participate in this study. It has been described
that ischaemic heart disease and diabetes are the main
contributors to the high costs of obesity, probably because
ischaemic heart disease treatment is expensive and dia-
betes is a disease that has the highest incidence risk in
people with obesity [27, 28]. Besides this, the mean BMI
and age in the Ghent study was higher and might have
lead to higher costs [29].
Based on extrapolation of data of three months, partic-
ipants of this study were on average 22 days absent from
Table 5 Spearman rank order correlation coefficients (Rho) matrix between costs, utility index, BMI, age and number of
comorbidities in this study sample
Utility Cost absenteeism Total cost
patient
Total cost
insurer
Total cost society BMI Age Number comorbidities
Utility 1.000 −0.395** −0.532** −0.501** −0.550** −0.303* −0.249 −0.443**
Cost absenteeism −0.395** 1.000 0.359** 0.371** 0.585** 0.140 0.178 0.201
Total cost patient −0.532** 0.359** 1.000 0.895** 0.886** 0.197 .291* 0.260*
Total cost insurer −0.501** 0.371** 0.895** 1.000 0.929** 0.222 0.194 0.201
Total cost society −0.550** 0.585** 0.886** 0.929** 1.000 0.182 0.189 0.190
BMI −0.303* 0.140 0.197 0.222 0.182 1.000 0.017 0.394**
Age −0.249 0.178 0.291* 0.194 0.189 0.017 1.000 0.168
Number
comorbidies
−0.443** 0.201 0.260* 0.201 0.190 0.394** 0.168 1.000
*: correlation is significant at the 0.05 level; **: correlation is significant at the 0.01 level
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work per year. This absenteeism rate is much higher
than that in the general population (14 days) [22]. The
simple extrapolation from three months of data towards
twelve months may have led to a bias of the yearly
absenteeism. However, this finding is consistent with the
findings of Seidell et al. who found increased absentee-
ism in obese females because of medical problems such
as mental health disorders or musculoskeletal problems
[30]. Both types of disorders were also prominent in the
sample of the present study. As the correlation matrix
showed (Table 5), productivity-loss may be an important
cost driver for the society and resulted in this sample in
a yearly average indirect cost of 6208.00 Euro.
Participants in the present study showed a mean utility
index score of 0.83 (SD = 0.141). This value is similar to
the utility score of the general population in Flanders [3]
and somewhat higher than the pilot study of the larger
Ghent area which showed a mean utility index score of
0.82 (SD = 0.12) [15]. About 13.5% of the sample showed
low utility index scores (< 0.70). Such scores are compar-
able with utility index scores reported by patients with
Parkinson disease (utility index = 0.58) [31] or severe
rheumatic disorder (utility index = 0.57) [32].
The sample in the present study consisted predomin-
antly of the so-called MHO [33] which resulted in aver-
age utilities and direct costs that were very similar to the
general population but importantly different from those
of the obese reference sample [15]. This can be illus-
trated by the fact that people were excluded when they
had musculoskeletal problems that made strength or
cardiovascular training impossible leading to exclusion
of severe osteoartitis. Also, it is stated that an increased
BMI is associated with reduced health-related quality of
life, even in the absence of metabolic comorbidities [34].
Four out of 59 participants reported high productivity
losses that resulted in yearly indirect costs of more than
103,680.00 Euro per person.
Nine out of the 59 participants showed five or more
comorbidities. In this subsample average costs increased
to 360.00 Euro (patient’s perspective), to 1256.00 Euro
(insurer’s perspective) and 10,160.00 Euro (societal per-
spective) while average utility was decreased to 0.73
(ranging from 0.45 to 1.00). In this regard, it can be con-
firmed that MHO do have an increased risk of diabetes
type 2 and coronary diseases in later life which indicates
that healthy obesity can be described as an intermediate
stage of disease progression accompanied with import-
ant health costs in later life [35, 36].
In this sample, a higher rate of unemployment was
seen in comparison with general female unemployment
rates in Flanders (7% vs. 4.5%). Although it is assumed
that there is a negative effect of obesity on employment,
mediated through disability resulting from the accumu-
lation of chronic conditions, there is also a possibility
that pre-existing conditions contribute to obesity at
baseline [37, 38].
Health-related costs in overweight or obese residents
in Flanders are as yet no well documented. This study
adds information to the findings of a pilot study that
was previously conducted using similar methods in a
sample of 62 obese males and females of the Ghent area
in Flanders [15]. Combined data and results of both
studies may help Flemish policy makers during their
decision making processes when planning actions to
contain the burden of overweight and obesity. For ex-
ample, the findings of this study may be used by health
economists as input data when modelling is needed in
cost-effectiveness studies. According to a recently con-
ducted research in Europe, overweight is responsible for
20–26% of the direct medical costs [28]. Research in
various countries showed that 2–5% of annual health-
care costs are attributable to overweight [8, 39–43].
This study was conducted on a sample that was
recruited to participate in a prospective randomized
controlled trial. Hence it was a captive sample, which
may explain the high response rate (59 out of 62) and
helped the researchers to ask participants if they had
doubts about the reporting or in case of missing values.
Despite this advantage, underreporting or overreporting
can never be excluded although it is reported in litera-
ture thatthe reconstruction of total costs based on
self-reported costs (cost diary) shows good agreement
with data from other sources such as from insurance
companies [44, 45].
Another limitation of this study is the fact that intan-
gible costs were omitted. For example the use of pain
medication was considerable in this sample, but the sub-
jectively felt “pain and suffering” was not calculated. Simi-
larly, tangible and intangible costs due to discrimination,
bullying or stigmatization were not calculated [46]. Since
welfare losses were not valued, the total economic burden
of overweight and obesity may be underestimated [47]. It
is recommended that future studies examining the eco-
nomic impact of overweight or obesity also examine the
intangible costs to catch the full economic burden [48]. It
can be suggested to determine non-financial welfare costs
using disability adjusted life years (DALYs) [49, 50].
In the sample under investigation, the average yearly
total cost from a societal perspective was 8958.8 Euro.
The fact that data from three months were extrapolated
to a whole year, might have led to a bias. Since no ap-
propriate recall periods are determined in cost-of-illness
studies, it is hard to identify whether it is better to col-
lect a short-term snapshot of resource use and extrapo-
late to a longer period or to ask questions covering a
broader period which potentially increases recall bias or
leads to more uncertainty and hance higher variability of
results [51, 52]. Often, costs are calculated based on the
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reported rates of comorbidities, or data from an insur-
ance company [40, 53]. In this study, a method was used
in which all costs were reported by participants over a
short period of three months. Extrapolation of the
short-term data (three month) to one year was used be-
cause of its patient-friendliness and proven validity [44].
Finally, this sample consisted MHO females without
diabetes or any other major comorbidity. Thus, the cost
results in this study are likely to underestimate the true
costs on population level of adult women with over-
weight and obesity.
Conclusion
On average, “healthy overweight or obese” non-diabetic
premenopausal females (mean age 37 years) of the Ant-
werp metropolitan area showed similar direct health
costs and health utility as compared to the general Flem-
ish female population. The observed high number of co-
morbidities and drug intake did not primarily lead to an
increased average direct medical cost. In contrast, aver-
age absenteeism was high in this sample and resulted in
important total costs from the societal perspective.
Overweight or obese persons are at increased risk for
disease such as diabetes mellitus type 2 later in life,
which may then cause even more important health costs.
A subsample of nine participants with five or more co-
morbidities showed already high costs and low health
utility as compared to the general population. Thus, sec-
ondary prevention to avoid health deterioration in MHO
females is needed to contain health care and social costs.
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